Saturday, 19 July 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 19 July 2025
News

Bayer closes in on Astellas' market

Posted 17 July 2025 AM

Bayer is closing in on Astellas with its own non-hormonal therapy for menopause.

The German pharma scored its first worldwide nod for Lynkuet in the UK last week, signalling that the TGA, which began reviewing the once-daily oral treatment in September 2024 will make a similar decision soon.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (15)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (4)

Devices (1)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.